Research Progress on the Role of Tumor Microenvironment in Glioma
DOI:
https://doi.org/10.53469/jcmp.2024.06(11).56Keywords:
Tumor microenvironment, Glioma, Molecular mechanism, Research progressAbstract
As a malignant tumor of the nervous system, the pathogenesis of glioma is still unclear. Through treatment methods such as surgery, radiotherapy, chemotherapy, immunotherapy, and electric field therapy, gliomas can achieve certain therapeutic effects, but there are still problems such as large adverse reactions and toxic side effects, which cause serious economic and psychological burdens to patients. In recent years, the tumor microenvironment (TME) has played an important role in the progression and treatment of gliomas, as it can delay the progression of gliomas and achieve therapeutic effects. In recent years, there have been many research achievements related to this, but there is a lack of systematic organization. Therefore, this study aims to systematically summarize the relevant mechanisms of TME in glioma, in order to provide new ideas for the treatment of glioma.
References
TAN A C, ASHLEY D M, LóPEZ G Y, et al. Management of glioblastoma: State of the art and future directions [J]. CA: a cancer journal for clinicians, 2020, 70(4): 299-312.
DAVIS M E. Glioblastoma: Overview of Disease and Treatment [J]. Clinical journal of oncology nursing, 2016, 20(5 Suppl): S2-8.
PENG Y, HUANG J, XIAO H, et al. Codelivery of temozolomide and siRNA with polymeric nanocarrier for effective glioma treatment [J]. International journal of nanomedicine, 2018, 13: 3467-3480.
ZHANG J, STEVENS M F, BRADSHAW T D. Temozolomide: mechanisms of action, repair and resistance [J]. Current molecular pharmacology, 2012, 5(1): 102-114.
ROH J, IM M, KANG J, et al. Long non-coding RNA in glioma: novel genetic players in temozolomide resistance [J]. Animal cells and systems, 2023, 27(1): 19-28.
JAROSZ-BIEJ M, SMOLARCZYK R, CICHON T, et al. Tumor Microenvironment as A "Game Changer" in Cancer Radiotherapy [J]. International journal of molecular sciences, 2019, 20(13): 3212.
DEBERARDINIS R J. Tumor Microenvironment, Metabolism, and Immunotherapy [J]. The New England journal of medicine, 2020, 382(9): 869-871.
LI Y, ZHAO L, LI X F. Hypoxia and the Tumor Microenvironment [J]. Technology in cancer research & treatment, 2021, 20: 15330338211036304.
ZHANG H, LUO Y B, WU W, et al. The molecular feature of macrophages in tumor immune microenvironment of glioma patients [J]. Computational and structural biotechnology journal, 2021, 19: 4603-4618.
KHAN F, PANG L, DUNTERMAN M, et al. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy [J]. The Journal of clinical investigation, 2023, 133(1).
GONZALEZ H, HAGERLING C, WERB Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression [J]. Genes & development, 2018, 32(19-20): 1267-1284.
Ni X, Wu W, Sun X, et al. Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against PTEN-null glioblastoma. Sci Adv. 2022;8(27):eabl5165.
LI J, KANEDA M M, MA J, et al. PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response [J]. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118(16).
LI Z, MENG X, WU P, et al. Glioblastoma Cell-Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance [J]. Cancer immunology research, 2021, 9(12): 1383-1399.
MATHIVET T, BOULETI C, VAN WOENSEL M, et al. Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth [J]. EMBO molecular medicine, 2017, 9(12): 1629-1645.
AKKARI L, BOWMAN R L, TESSIER J, et al. Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance [J]. Science translational medicine, 2020, 12(552).
YANG X, SHEN H, LI Q, et al. Interference of P2X4 receptor expression in tumor-associated macrophages suppresses migration and invasion of glioma cells [J]. Nan Fang Yi Ke Da Xue Xue Bao, 2022, 42(5): 658-664.
KIM H J, PARK J H, KIM H C, et al. Blood monocyte-derived CD169(+) macrophages contribute to antitumor immunity against glioblastoma [J]. Nature communications, 2022, 13(1): 6211.
CHEN Z, ZHUO S, HE G, et al. Prognosis and Immunotherapy Significances of a Cancer-Associated Fibroblasts-Related Gene Signature in Gliomas [J]. Frontiers in cell and developmental biology, 2021, 9: 721897.
MAEDA M, TAKESHIMA H, IIDA N, et al. Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3 [J]. Gut, 2020, 69(2): 243-251.
MONTERAN L, EREZ N. The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment [J]. Frontiers in immunology, 2019, 10: 1835.
LINARES J, MARíN-JIMéNEZ J A, BADIA-RAMENTOL J, et al. Determinants and Functions of CAFs Secretome During Cancer Progression and Therapy [J]. Frontiers in cell and developmental biology, 2020, 8: 621070.
LI M, LI G, KIYOKAWA J, et al. Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma [J]. Acta neuropathologica communications, 2020, 8(1): 221.
ZHAO J, YANG S, LV C, et al. Cancer-associated fibroblasts suppressed ferroptosis in glioblastoma via upregulating lncRNA DLEU1 [J]. American journal of physiology Cell physiology, 2023, 324(5): C1039-c1052.
PAIJENS S T, VLEDDER A, DE BRUYN M, et al. Tumor-infiltrating lymphocytes in the immunotherapy era [J]. Cellular & molecular immunology, 2021, 18(4): 842-859.
KAZEMI M H, SADRI M, NAJAFI A, et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? [J]. Frontiers in immunology, 2022, 13: 1018962.
LIN B, DU L, LI H, et al. Tumor-infiltrating lymphocytes: Warriors fight against tumors powerfully [J]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, 132: 110873.
MATHEWSON N D, ASHENBERG O, TIROSH I, et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis [J]. Cell, 2021, 184(5): 1281-1298.e1226.
DI W, FAN W, WU F, et al. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples [J]. Cancer science, 2022, 113(2): 756-769.
GIERYNG A, PSZCZOLKOWSKA D, WALENTYNOWICZ K A, et al. Immune microenvironment of gliomas [J]. Laboratory investigation; a journal of technical methods and pathology, 2017, 97(5): 498-518.
WANG G, WANG W. Advanced Cell Therapies for Glioblastoma [J]. Frontiers in immunology, 2022, 13: 904133.
DAUBON T, HEMADOU A, ROMERO GARMENDIA I, et al. Glioblastoma Immune Landscape and the Potential of New Immunotherapies [J]. Frontiers in immunology, 2020, 11: 585616.
BERGER G, KNELSON E H, JIMENEZ-MACIAS J L, et al. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models [J]. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119(28): e2111003119.
SHAIM H, SHANLEY M, BASAR R, et al. Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cells [J]. The Journal of clinical investigation, 2021, 131(14).
JIN X, KANG J, LU Q, et al. Fc gamma receptor IIb in tumor-associated macrophages and dendritic cells drives poor prognosis of recurrent glioblastoma through immune-associated signaling pathways [J]. Frontiers in genetics, 2022, 13: 1046008.
SHUI Y, HU X, HIRANO H, et al. Combined phospholipids adjuvant augments anti-tumor immune responses through activated tumor-associated dendritic cells [J]. Neoplasia (New York, NY), 2023, 39: 100893.
INOGéS S, TEJADA S, DE CERIO A L, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients [J]. Journal of translational medicine, 2017, 15(1): 104.
LIAU L M, ASHKAN K, TRAN D D, et al. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma [J]. Journal of translational medicine, 2018, 16(1): 142.
SUVà M L, TIROSH I. The Glioma Stem Cell Model in the Era of Single-Cell Genomics [J]. Cancer cell, 2020, 37(5): 630-636.
VINIK Y, ORTEGA F G, MILLS G B, et al. Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response [J]. Science advances, 2020, 6(40).
Gao Jiancheng, Lu Chenfei, Zhang Zifeng, et al. Extracellular vesicles derived from glioma stem cells promote malignant progression of glioma [J] Journal of Nanjing Medical University (Natural Science Edition), 2022, 42 (12): 1658-1663.
NIU W, XIAO Q, WANG X, et al. A Biomimetic Drug Delivery System by Integrating Grapefruit Extracellular Vesicles and Doxorubicin-Loaded Heparin-Based Nanoparticles for Glioma Therapy [J]. Nano letters, 2021, 21(3): 1484-1492.
GROVER A, SANSEVIERO E, TIMOSENKO E, et al. Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic [J]. Cancer discovery, 2021, 11(11): 2693-2706.
BAYIK D, BARTELS C F, LOVRENERT K, et al. Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets [J]. Cancer research, 2022, 82(22): 4274-4287.
LI K, SHI H, ZHANG B, et al. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer [J]. Signal transduction and targeted therapy, 2021, 6(1): 362.
LIU H, WEI Z, ZHANG Y, et al. TGF-β based risk model to predict the prognosis and immune features in glioblastoma [J]. Frontiers in neurology, 2023, 14: 1188383.
Liu Minting, Dai Lijun, Zhang Zhenbin, et al. Preliminary study on the detection of immune microenvironment in glioblastoma by transforming growth factor-β combined with CD3+, CD4+, CD8+T cells [J] Chinese Journal of Modern Neurological Diseases, 2023, 23 (03): 247-253.
YAN T, TAN Y, DENG G, et al. TGF-β induces GBM mesenchymal transition through upregulation of CLDN4 and nuclear translocation to activate TNF-α/NF-κB signal pathway [J]. Cell death & disease, 2022, 13(4): 339.
JOSEPH J V, MAGAUT C R, STOREVIK S, et al. TGF-β promotes microtube formation in glioblastoma through thrombospondin 1 [J]. Neuro-oncology, 2022, 24(4): 541-553.
ZHANG X, WANG G, GONG Y, et al. IGFBP3 induced by the TGF-β/EGFRvIII transactivation contributes to the malignant phenotype of glioblastoma [J]. iScience, 2023, 26(5): 106639.
AHMAD A, NAWAZ M I. Molecular mechanism of VEGF and its role in pathological angiogenesis [J]. Journal of cellular biochemistry, 2022, 123(12): 1938-1965.
AHIR B K, ENGELHARD H H, LAKKA S S. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma [J]. Molecular neurobiology, 2020, 57(5): 2461-2478.
HARRIS R, MINERS J S, ALLEN S, et al. VEGFR1 and VEGFR2 in Alzheimer's Disease [J]. Journal of Alzheimer's disease: JAD, 2018, 61(2): 741-752.
CHEN L, XIE X, WANG T, et al. ARL13B promotes angiogenesis and glioma growth by activating VEGFA-VEGFR2 signaling [J]. Neuro-oncology, 2023, 25(5): 871-885.
CHRYPLEWICZ A, SCOTTON J, TICHET M, et al. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity [J]. Cancer cell, 2022, 40(10): 1111-1127.e1119.
SZKLENER K, MAZUREK M, WIETESKA M, et al. New Directions in the Therapy of Glioblastoma [J]. Cancers, 2022, 14(21).
WIDODO S S, DINEVSKA M, FURST L M, et al. IL-10 in glioma [J]. British journal of cancer, 2021, 125(11): 1466-1476.
LIU H, ZHAO Q, TAN L, et al. Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma [J]. Cancer cell, 2023, 41(4): 693-710.e698.
ZHA C, MENG X, LI L, et al. Neutrophil extracellular traps mediate the crosstalk between glioma progression and the tumor microenvironment via the HMGB1/RAGE/IL-8 axis [J]. Cancer biology & medicine, 2020, 17(1): 154-168.
SUN Y, ZHANG Z, ZHANG C, et al. An effective therapeutic regime for treatment of glioma using oncolytic vaccinia virus expressing IL-21 in combination with immune checkpoint inhibition [J]. Molecular therapy oncolytics, 2022, 26: 105-119.
VAN LOO G, BERTRAND M J M. Death by TNF: a road to inflammation [J]. Nature reviews Immunology, 2023, 23(5): 289-303.
RATAJCZYK E, LEDZEWICZ U, LESZCZYNSKI M, et al. The role of TNF-α inhibitor in glioma virotherapy: A mathematical model [J]. Mathematical biosciences and engineering: MBE, 2017, 14(1): 305-319.
ZHU X, SHI G, LU J, et al. Potential regulatory mechanism of TNF-α/TNFR1/ANXA1 in glioma cells and its role in glioma cell proliferation [J]. Open life sciences, 2022, 17(1): 208-220.
GONG B, GUO D, ZHENG C, et al. Complement C3a activates astrocytes to promote medulloblastoma progression through TNF-α [J]. Journal of neuroinflammation, 2022, 19(1): 159.
LEI Q, GU H, LI L, et al. TNIP1-mediated TNF-α/NF-κB signalling cascade sustains glioma cell proliferation [J]. Journal of cellular and molecular medicine, 2020, 24(1): 530-538.
JIN L, GE H, LONG Y, et al. CD70, a novel target of CAR T-cell therapy for gliomas [J]. Neuro-oncology, 2018, 20(1): 55-65.
SEYFRID M, MAICH W T, SHAIKH V M, et al. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment [J]. Journal for immunotherapy of cancer, 2022, 10(1).
LIU C, LIU J, SHAO J, et al. MAGED4B Promotes Glioma Progression via Inactivation of the TNF-α-induced Apoptotic Pathway by Down-regulating TRIM27 Expression [J]. Neuroscience bulletin, 2023, 39(2): 273-291.
Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma Subclassifications and Their Clinical Significance. Neurotherapeutics. 2017;14(2):284-297.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Fan Qi, Xiaoping Zhao
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
